MON-LB032 Real World Evidence Data on the Role of Sodium/Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonist in Chronic Kidney Disease Stage 3 Patients beyond Glycemic Control, at Glycemia Clinic- Kuwait

Introduction Diabetes remain the most common reason for progression to end stage renal disease. Chronic kidney disease (CKD) is a strong prediction of mortality in patients with diabetes. 1 Up to 40% of type two diabetes (T2D) will eventually suffer from kidney failure. 2 Sodium/glucose Cotransporter 2 inhibitors (SGLT2) regularly cause a reduction in Glomerular filtration rate (eGFR) by around 5ml/min/1.73 m 2 as well as a reduction in urine microalbumin by 30%-40%. 3 SGLT2 inhibitors are also associated with reduction in uric acid and weight. Both high levels of uric acid and obesity are risk factors for diabetic nephropathy and progression of CKD. 4 While it was found that studies used Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) in patients with higher degree of renal impairment was very limited. However, GLP-1 RA was associated with a urine microalbumin and Hba1c reduction. 5 Efficacy of SGLT2 and GLP-1 RA is well documented, though SGLT2 is contraindicated with an eGFR